AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04157348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Benralizumab
Description: Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
Study NCT06410066 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01660763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab PCA System/15 mcg
Description: 15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
Study NCT01660763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sufentanil NanoTab PCA System
Description: Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
Study NCT00477191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
Study NCT01289067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Satraplatin
Description: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
Study NCT01232257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 4 gifts of N-acetylcysteine 600 mg BID
Study NCT04242186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Liaison Service
Description: The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
Study NCT03735784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based health discussions
Description: Create interactions between the employees.
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOScuisine website
Description: Site that is personalized to the employee. It provides menus, grocery shopping list and other.
Study NCT00781625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: UREX-cap-5
Description: Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
Study NCT00781625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Y cap G-3
Description: Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
Study NCT01694537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
Study NCT01694537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DLBS1033
Description: The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
Study NCT01694537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo is made with same size and shape with study drug.
Study NCT01694537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is made with same size and shape with study drug.
Study NCT01042457 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil
Description: Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
Study NCT00035126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Study NCT01024322 — intervention group
Intervention type: DRUG
Intervention: Ciprofloxicine or Vigamox or other.
Description: Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
Study NCT01024322 — intervention group
Intervention type: DRUG
Intervention: Nonsteroidal (Acular, Voltaren Xibrom, etc)
Description: Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
Study NCT02570165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
Study NCT02570165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/ Vilanterol
Description: Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
Study NCT01024322 — intervention group
Intervention type: DRUG
Intervention: Steroid (FML, Pred Forte, Flarex, etc.)
Description: Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
Study NCT02570165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
Study NCT00572234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion SR
Description: 12 week course of bupropion SR 150 mg, BID
Study NCT01953783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity.
Study NCT03438799 — intervention group
Intervention type: DEVICE
Intervention: Cordio System
Description: App, cloud and web device
Study NCT02764489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.
Study NCT00415532 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medical Standard of Care for ITP
Study NCT00415532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study NCT04657510 — intervention group
Intervention type: OTHER
Intervention: COVID-19
Description: Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
Study NCT03128593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
Study NCT00515073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m\^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m\^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
Study NCT00515073 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic Radiation
Description: Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
Study NCT00515073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg IV given 30 minutes prior to chemotherapy
Study NCT00515073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: 300 mg IV given 30 minutes prior to chemotherapy
Study NCT00515073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg IV given 30 minutes prior to chemotherapy
Study NCT00933660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERC-training by instructor
Description: Standard way of training with an instructor
Study NCT00933660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based training only
Description: Experimental way of training with a web based training application
Study NCT00933660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based training with a personal training manikin
Description: Experimental way of training with a web based training application and a simple personal training manikin
Study NCT05081674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alectinib
Description: 600mg 1OD
Study NCT05081674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200mg every 21 days
Study NCT05081674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 6mg/kg every 4 weeks
Study NCT02255799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
Study NCT02255799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily for 70 days.
Study NCT05081674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg
Study NCT02287337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: High velocity low amplitude thrust joint manipulation to cervical spine facet joints
Study NCT02287337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise
Description: Therapeutic exercises to the cervical, thoracic and scapular musculature
Study NCT02287337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Therapeutic exercises to the cervical, thoracic and scapular musculature
Study NCT02528578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermal stimulation delivered by a thermode.
Description: Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
Study NCT02528578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
Study NCT02608359 — intervention group
Intervention type: DRUG
Intervention: Abiraterone Acetate
Description: This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
Study NCT03804788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
Study NCT04363411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: finger prick screening for BBV infections and questionnaires by outreaching methodology
Description: Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
Study NCT03804788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygeine
Description: All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
Study NCT03804788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygeine
Description: All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
Study NCT00630669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rubber band ligation
Description: placing rubber bands around the internal hemorrhoids
Study NCT00630669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation
Description: using electricity to cauterize
Study NCT00593333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade Intramedullary Nail
Description: Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
Study NCT00593333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigen Trochanteric Femoral Nail
Description: Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
Study NCT00660790 — intervention group
Intervention type: OTHER
Intervention: Intensified Treatment of risk factors
Description: Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
Study NCT03287466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: targeted oxygen therapy
Study NCT03287466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: targeted oxygen therapy
Study NCT01557491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Straight Incision
Description: The incision will be made at a 90 degree angle to the surface of the scalp
Study NCT01557491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevelled Incision
Description: The Incision will be made at a 45 degree angle to the surface of the scalp.
Study NCT03557710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Devaluing energy-dense foods for cancer-control
Description: A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
Study NCT03557710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Devaluing energy-dense foods for cancer-control
Description: A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
Study NCT02780661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture Cleanser Daily Use Period
Description: One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
Study NCT02780661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture Cleanser Weekly Use Period
Description: One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
Study NCT02780661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
Study NCT05521750 — intervention group
Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health screening
Description: Screen for diabetes, cholesterol, blood pressure and body weight.
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closing events
Description: these aim to motivate the employees to continue into the program.
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Health platform
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerometer provided
Description: Social Health Platform: employees can challenge themselves or each other.
Study NCT04503148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
Study NCT04503148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled General Anesthetics
Description: Sevoflurane or desflurane for induction and maintenance of anesthesia
Study NCT02884050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: antiepilepsy drug
Study NCT02884050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active placebo
Study NCT04117360 — intervention group
Intervention type: OTHER
Intervention: Orthognathic surgery and Orthodontics
Description: This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
Study NCT03618394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: MCT/ω-3-PUFA
Description: lipid emulsion
Study NCT03618394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Soybean Based
Description: lipid emulsion
Study NCT02482805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Exposure therapy for social anxiety disorder
Study NCT02711696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GCED, Gluten Contamination Elimination Diet
Description: A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED).
Study NCT01449656 — intervention group
Intervention type: DEVICE
Intervention: LMA Proseal: control device
Description: LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization